HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
MDXH
MDxHealth S.A.
There isn't enough reported data to score MDXH yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
MDXH Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
MDXH's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
MDXH PE Valuation
MDXH has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
MDXH Forward outlook
There aren't enough analyst estimates for MDXH to show an outlook.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
MDXH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q4 2025 | -$0.67 | +$0.49 |
| Q4 2024 | -$1.16 | +$0.50 |
| Q4 2023 | -$1.66 | +$1.14 |
MDXH and HIMS do not have enough comparable growth data to identify a winner.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS's revenue has grown year over year every quarter since late 2021: $890M last quarter, up 49% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
MDXH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2025 | $107.9M | +20% |
| Q4 2024 | $90M | +28% |
| Q4 2023 | $70.2M | +89% |
| Q4 2022 | $37.1M | +67% |
| Q4 2021 | $22.2M | +159% |
| Q4 2020 | $8.6M | +841% |
| Q2 2020 | $9.9M | -9.1% |
| Q4 2019 | $912K | -92% |
MDXH has the edge over HIMS in the latest year-over-year revenue comparison.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2025 | -13% | +107 points |
| Q4 2024 | -27% | +137 points |
| Q4 2023 | -39% | +93 points |
| Q4 2022 | -102% | +2766 points |
| Q4 2021 | -121% | +6.8 points |
| Q4 2020 | -165% | -12 points |
| Q2 2020 | -131% | -45 points |
| Q4 2019 | -2868% | -2790 points |
MDXH's operating margin was −13% last quarter, up 107 points from the same quarter a year ago, near the top of its range since 2009.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS still generates free cash flow, though less than at its 2024 peak: $8M over the past year.
MDXH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2025 | -$3.3M | +$16.4M |
| Q4 2024 | -$19.7M | +$4.5M |
| Q4 2023 | -$24.2M | +$12.7M |
| Q4 2022 | -$36.9M | -$13.5M |
| Q4 2021 | -$23.4M | -$14.1M |
| Q4 2020 | -$9.4M | -$863K |
| Q2 2020 | -$11.4M | +$2.4M |
| Q4 2019 | -$8.5M | -$1.7M |
MDXH has burned cash in almost every quarter: −$84M over the past year, against −$53M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over MDXH on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
MDXH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +52% | +17.1M shares |
| 1 year | +454% | +40.9M shares |
| 3 years | +966% | +45.3M shares |
| 5 years | +2164% | +47.8M shares |
| Available history | +3691% | +48.6M shares |
MDXH has 50M diluted shares, up 454% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q2 2020 | — |
| Q4 2019 | — |
| Q2 2019 | — |
| Q4 2018 | — |
| Q2 2018 | — |
| Q4 2017 | — |
| Q2 2017 | — |
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
MDXH Net Leverage
MDXH's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
MDXH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 24.4 | Oversold |
| Stochastic | 0.7 | Oversold |
MDXH's weekly RSI is 24 (oversold) and its Stochastic is 1 (oversold).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
MDXH PE vs Healthcare Sector
MDXH has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
MDXH has stronger trend alignment. HIMS is above 0 of 5 weekly averages versus MDXH above 0 of 4.
MDXH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.32 | 56% below |
| 20 week MA | $0.48 | 71% below |
| 50 week MA | $1.68 | 92% below |
| 100 week MA | $2.14 | 93% below |
MDXH is in a downtrend: it's below all four of its weekly moving averages, and 93% below its 100-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over MDXH on returns for 2026, with the stronger performance.
MDXH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2023 | $3.07 | $3.94 | +28% |
| 2024 | $3.94 | $2.31 | -41% |
| 2025 | $2.31 | $3.41 | +48% |
| 2026 YTD | $3.41 | $0.14 | -96% |
MDXH is down 96% so far in 2026, after finishing higher in two of the previous three years.